Navigation Links
Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
Date:10/3/2007

s debilitating disease."

Over 400,000 Americans have multiple sclerosis (MS), and worldwide MS may affect over 2.5 million individuals. MS is an autoimmune disease in which the individuals' immune system responds against multiple components of nerve- insulating myelin. The effects of these immune-mediated attacks can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.

About Peptimmune

Peptimmune, Inc. is a privately held clinical stage biotechnology company focused on the development of peptide therapies to improve the management of chronic autoimmune and inflammatory disorders. The Company is in clinical development with second-generation therapeutics that are expected to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. Current investors include New Enterprise Associates, MPM Capital, Prism Venture Partners, Vanguard Ventures, Hunt Ventures, Boston Medical Investors, Silicon Valley Bank Capital, Itochu Corporation, and Genzyme Corporation. For additional information, access our website at http://www.peptimmune.com .


'/>"/>
SOURCE Peptimmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Malvern initiates European user group meetings for chemical imaging
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... VIENNA , July 29, 2014 ... Vienna, Austria will present data from a ... that aims to slow or stop Parkinson,s disease progression. ... a $ 1.5 million grant and will discuss the impact ... community. When:   Thursday, July 31, 2014 ...
(Date:7/29/2014)... 2014   Abide Therapeutics announced today ... its board of directors. Thornberry was previously senior ... for Merck & Co. Inc., where she led ... in diabetes, osteoporosis, fertility and contraception. Thornberry, a ... that resulted in the discovery of Januvia TM ...
(Date:7/29/2014)... Today, Frost & Sullivan recognizes Validic ... Practices Award for Customer Value Leadership. The Validic ... connects digital health application developers, medical devices and ... prevention and wellness companies, population health management companies ... Frost & Sullivan presents this award to a ...
Breaking Medicine Technology:Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4
(Date:7/29/2014)... Some people can handle stressful situations better than ... Even identical twins show differences in how they ... pattern in the brains of genetically identical mice ... in stressful situations. , The findings, published ... eventually help researchers prevent potential consequences of chronic ...
(Date:7/29/2014)... 29, 2014 Healthcare staffing agency ... Nurses of Tomorrow Scholarship Competition winners:, ... NV ,     Racheal D., Freshman, Cerritos College ... Houston Community College in Houston, TX ... Medical Solutions hosts the Nurses of Tomorrow Scholarship ...
(Date:7/29/2014)... 29, 2014 Catalent Pharma Solutions, ... advanced delivery technologies for pharmaceutical, biologic, and consumer ... R&D Director and US Platform Leader of Pharmaceutical ... Drugs with Lipid-Based Formulations using Soft Capsule Delivery ... the Japan Society of Drug Delivery Systems (30-31 ...
(Date:7/29/2014)... The Affordable Care Act has created a ... Studies show that over 400 hospitals probably won’t survive ... tool that great hospitals use to survive the threat ... Their secret? Debriefing - the simple process of systematically ... an operational event. Debriefing is a standard procedure in ...
(Date:7/29/2014)... Dennis Thompson HealthDay Reporter ... live an average three years longer than people who don,t run, ... this study is that it appears that you can reap this ... every day, the 15-year study suggests. "People may not ... author Duck-chul Lee, an assistant professor of kinesiology at Iowa State ...
Breaking Medicine News(10 mins):Health News:A new brain-based marker of stress susceptibility 2Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2Health News:Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Running Could Add 3 Years to Your Lifespan 2Health News:Running Could Add 3 Years to Your Lifespan 3
... Dr. Neil Kurtz Resigns as President and Chief Executive Officer; ... Graham Appointed Acting Chief Executive Officer -, LA ... ) today announced that Neil Kurtz, M.D., is,resigning as President, ... of August 31, 2008. Dr. Kurtz is leaving TorreyPines,to assume ...
... genetic variation , , FRIDAY, Aug. 8 (HealthDay News) -- A ... salt intake and high blood pressure. , The study, which ... possible genetic factor that might make people more or less ... -- variants of a gene for angiotensinogen, a molecule that ...
... polar opposite diseases, but both depend upon dopamine in ... drug addicts get too much of it. Although the ... known, the way it works has been a mystery. ... Medicine has revealed that dopamine strengthens and weakens the ...
... release is available in French . , ... that patients who receive early treatment for Hepatitis C ... develop a rapid poly-functional immune response against HCV similar ... new study published in the Journal of Virology ...
... Delayed diagnosis, less successful surgery, pair of studies finds , , ... for prostate cancer may not be accurate for obese men, ... less likely to be effective for them, a new pair ... be diagnosed with an aggressive form of the disease," said ...
... in Senior Housing Growing; Adoption of Healthy Lifestyle ... ... the face of conventional,wisdom, which has long proven true, women live longer ... than ever are moving,into senior living residences nationwide. Historically female-dominated,senior living communities ...
Cached Medicine News:Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 2Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 3Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 4Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 5Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 6Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 7Health News:Too Much Salt Boosts Blood Pressure 2Health News:Why dopamine freezes parkinson patients and drives drug addicts 2Health News:Why dopamine freezes parkinson patients and drives drug addicts 3Health News:Early treatment is key to combating hepatitis C virus 2Health News:Obese Men Face Twin Threat From Prostate Cancer 2Health News:More Men Moving Into Senior Residences 2Health News:More Men Moving Into Senior Residences 3
Single step suture passage is made simple with Arthro-Pierce instruments. The low profile, highly sharpened tip allows easy passage through tissue in order to retrieve or apply suture....
12" suture passer...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Medicine Products: